| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Oakley Andrew John | Director | C/O ONCONETIX, INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI | /s/ Andrew Oakley | 19 Aug 2025 | 0002059152 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ONCO | Common Stock | Other | $0 | +20 | $0.000000 | 20 | 15 Aug 2025 | Direct | F1, F2 | |
| transaction | ONCO | Common Stock | Award | $0 | +618 | +3090% | $0.000000 | 638 | 15 Aug 2025 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Represents a restricted stock award originally granted to the Reporting Person on March 23, 2025 pursuant to the Issuer's 2022 Equity Incentive Plan, as amended ("2022 Plan" and the grant on such date, the "Original Award"). On August 15, 2025, the Original Award was modified to change the vesting terms, such that the award, which was to vest in full on August 31, 2025, was changed to vest in full on August 31, 2026, so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. Except as set forth herein, the Original Award remains unmodified. |
| F2 | On June 13, 2025, the Issuer effected a 1-for-85 reverse split of its Common Stock. The amounts set forth herein are presented on a post-split basis. |
| F3 | Represents a restricted stock award granted to the Reporting Person pursuant to the 2022 Plan. The award will vest in full on August 31, 2026 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date. |